SES Expands O3b mPOWER Technology Ecosystem with Modem Platform Partnerships
3.11.2020 10:50:00 EET | Business Wire | Press release
SES today announced Gilat and ST Engineering iDirect as its latest technology partners who will be developing the core infrastructure modem platforms for O3b mPOWER, SES’s ground-breaking non-geostationary-satellite orbit (NGSO) communications system.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201102006117/en/
SES Expands O3b mPOWER Technology Ecosystem with Modem Platform Partnerships (Graphic: Business Wire)
Gilat and ST Engineering iDirect were selected based on their next-generation modem technologies. Featuring open architectures with a path to full virtualisation, the modems will interface with SES’s differentiated Adaptive Resource Control (ARC) capability and leverage SES’s use of the Open Networking Automation Platform (ONAP) standard. The combination of this and other technologies will give SES the ability to dynamically control and optimise the entire O3b mPOWER system across space and ground infrastructure, enabling the efficient delivery of low-latency and high-throughput satellite-based data services that can be truly customised to fit specific connectivity requirements on land, at sea or in the air anywhere in the world.
O3b mPOWER is SES’s next-generation medium Earth orbit (MEO) communications system. It is currently under construction and on track for launch in 2021. The high-throughput satellites, as well as automated and intelligence-powered ground infrastructure, will deliver low-latency managed services from hundreds of Mbps up to multiple Gbps.
"We are honoured to have been selected by SES, our long-time strategic partner, to provide our next-generation baseband platform for O3b mPOWER. Gilat's innovative ground segment significantly reduces cost-per-bit, delivers a step-change in modem performance, and further integrates with and optimises SES ground and space service delivery," said Ron Levin Vice President Mobility and Global Accounts at Gilat. "Throughout the last year, we have been working closely with SES to develop the platform for O3b mPOWER with the joint goal of bringing to market unparalleled customer experience in all target verticals.”
“We are at the beginning of a new future for our industry. To be selected for O3b mPOWER is a tremendous validation of ST Engineering iDirect's technology vision and proves that ground infrastructure will play a pivotal role in SES’s ambitious goal to transform satellite service delivery,” said Frederik Simoens, CTO, ST Engineering iDirect. “O3b mPOWER is at the forefront of a significant movement to drive a standards-based, virtualised network approach where ground is in lockstep with space. Through our partnership, we will greatly expand the possibilities for global connectivity.”
“The basis of our O3b mPOWER communications system is defined and advanced by a diverse and robust partner ecosystem. As an industry, we are able to embrace the vision of open networking and seamless satellite services because of like-minded partners such as Gilat and ST Engineering iDirect who understand the step-change in system flexibility and capacity that O3b mPOWER will deliver,” said Stewart Sanders, SES’s Executive Vice President of Technology and O3b mPOWER programme manager. “We have first-hand experience over many years of working with both Gilat and ST Engineering iDirect and have always been impressed with their work as well as what their technologies can provide. Hence, we have full confidence in selecting these two outstanding companies as trusted partners for O3b mPOWER and to deliver a key part of our infrastructure supporting an unparalleled customer experience.”
Focused on making satellites a seamless part of global network solutions, SES has been steadily expanding its O3b mPOWER partner ecosystem. In addition to Gilat and ST Engineering iDirect, SES has also announced O3b mPOWER partnerships with SpaceX for launches, ALCAN, Isotropic Systems and Viasat for customer edge terminals, Amdocs for NFV technology, Kythera Space Solutions for the ARC software, Microsoft for gateways, and IBM and Microsoft for cloud connectivity.
Follow us on:
Social Media
Blog
Media Library
About SES
SES has a bold vision to deliver amazing experiences everywhere on earth by distributing the highest quality video content and providing seamless connectivity around the world. As the leader in global content connectivity solutions, SES operates the world’s only multi-orbit constellation of satellites with the unique combination of global coverage and high performance, including the commercially-proven, low-latency Medium Earth Orbit O3b system. By leveraging a vast and intelligent, cloud-enabled network, SES is able to deliver high-quality connectivity solutions anywhere on land, at sea or in the air, and is a trusted partner to the world’s leading telecommunications companies, mobile network operators, governments, connectivity and cloud service providers, broadcasters, video platform operators and content owners. SES’s video network carries over 8,300 channels and has an unparalleled reach of 367 million households, delivering managed media services for both linear and non-linear content. The company is listed on Paris and Luxembourg stock exchanges (Ticker: SESG). Further information is available at: www.ses.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201102006117/en/
Contact information
For further information please contact:
Suzanne Ong
External Communications
Tel. +352 710 725 500
suzanne.ong@ses.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 10:19:00 EEST | Press release
Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patients with unmet needs.” Pembrolizumab is a humanized monoclonal antibody that acts as an immune checkpoint inhibitor by targeting and blocking the programmed cell death protein 1 (PD-1) receptor on T cells. It is used to treat vari
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 10:00:00 EEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 10:00:00 EEST | Press release
Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European Medicines Agency (EMA) for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/DDC inhibitor-based treatment regimens. CHMP recommendation is based on data from the Phase 3 RISE-PD trial, which compared Hopledo® with immediate release levodopa/carbidopa (LD/CD) formulation in patients with Parkinson’s disease and moderate to severe motor fluctuations. In the study, Hopledo® demonstrated a significant increase in Good ON time over immediate release LD/CD with fewer daily doses and a comparable safety profile1. Hopledo® is a first-in-class, oral, modified-release formulation of LD/CD designed for the treatment of fluctuations of Parkinson’s diseas
Enhertu ® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 09:30:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across three phase 2 trials, including DESTINY-PanTumor02, DESTINY-Lung01 and DESTINY-CRC02. In DESTINY-PanTumor02, Enhertu demonstrated a confirmed objective response rate (ORR) of 52.3% (95% confidence interval [CI]: 42.6-6
Beerenberg Prevails in Patent Case Against Aspen Aerogels29.6.2026 08:00:00 EEST | Press release
The Korean Patent Court has invalidated three of Aspen Aerogels’ patents related to improved hydrophobic aerogel material. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260628192007/en/ Beerenberg delivers high-end insulation solutions built for performance, reliability, and long-term value. (Photo: Beerenberg) The ruling confirms the conclusion of the Intellectual Property Trial and Appeal Board (IPTAB) that the patents did not meet the necessary requirements for patentability. Beerenberg, which specializes in high-end insulation products, welcomes the court’s decision. “We are pleased that the case has now been concluded and that any uncertainty regarding the infringement claims has been removed,” says CEO Arild Apelthun. About Beerenberg Beerenberg has delivered cost-efficient solutions to a wide range of industrial enterprises for 49 years. The company is one of the leading suppliers of maintenance and modification serv
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
